LEO 32731 - A Phase I, Single-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects.
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Orismilast (Primary)
- Indications Inflammation
- Focus Adverse reactions
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Apr 2012 Planned end date changed from Oct 2011 to Aug 2012 added as reported by ClinicalTrials.gov.
- 04 Apr 2011 Status chnaged from not yet recruiting to recruiting as reported by ClinicalTrials.gov.